Khảo sát các phản ứng bất lợi sau tiêm vaccine phòng Covid-19 của Astrazeneca tại Bệnh viện Quốc tế Vinmec Đà Nẵng từ 1/8 đến 22/9/2021

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Kim Long Hoàng, Trà Linh Hoàng, Diệu Hiền Phan, Thất Trí Dũng Tôn

Ngôn ngữ: vie

Ký hiệu phân loại: 362.1962414 Physical illness

Thông tin xuất bản: Tạp chí Y học TP. Hồ Chí Minh, 2022

Mô tả vật lý: 60-67

Bộ sưu tập: Metadata

ID: 499609

Thêm vào giỏ

Nghiên cứu được tiến hành để đánh giá tỉ lệ và mức độ nặng của các phản ứng bất lợi sau tiêm chủng (Adverse Events Following Immunization-AEFI) liên quan đến vaccine COVID-19 của AstraZeneca và xác định yếu tố liên quan đến các AEFI này ở người Việt Nam. Phương pháp: Một khảo sát trực tuyến truy cập qua mã QR được tiến hành ở những người Việt Nam trưởng thành có tiêm vaccine COVID-19 của AstraZeneca tại bệnh viện Quốc tế Vinmec Đà Nẵng từ 1/8 đến 22/9/2021. Nghiên cứu thu thập thông tin dịch tễ chung và các AEFI trong thời gian 7 ngày từ khi bắt đầu tiêm và xác định mối liên quan giữa một số yếu tố và tỉ lệ AEFI. Kết quả: Có tổng cộng 878 người tham gia vào nghiên cứu với độ tuổi trung bình là 34,5 ± 9,9 tuổi. 28,8% người tham gia gặp phải ít nhất một AEFI. Phần lớn các AEFI ở mức độ nhẹ (28,4%), trong khi đó, chỉ có khoảng 4,7% người tiêm báo cáo có các AEFI nặng. Tỉ lệ người tiêm gặp AEFI cao nhất vào khoảng 24 giờ đầu và hầu như rất ít phản ứng kéo dài quá 2 ngày sau tiêm. Các AEFI thường gặp nhất sau tiêm bao gồm đau tại vị trí tiêm (22,8%), đau đầu (19,6%), đau cơ (18,7%), sốt ≥ 37,5oC (13,3%) và ớn lạnh (11,6%). Phân tích dữ liệu từ nghiên cứu cho thấy có sự liên quan giữa tuổi tác và tỉ lệ người tiêm gặp AEFI (p=0,001). Không có sự khác biệt đáng kể về tỉ lệ AEFI giữa nam và nữ (p=0,353).This study aims to evaluate the incidence and severity of Adverse Event Following Immunization (AEFI) associated with COVID-19 vaccine AstraZeneca and identify factors affecting these AEFIs in Vietnamese people. Method: An online survey accessed by scanning QR code was conducted among Vietnamese adults who had COVID-19 vaccine AstraZeneca injection from August 1st to September 22nd, 2021 in Vinmec International Hospital in Da Nang City. We investigated the demographic characteristics, AEFIs during the 7 days following the vaccination and identified the correlation between some factors and the incidence of AEFIs. Results: A total of 878 participants were included in our study and the mean age of the subjects was 34.5 ± 9.9 years old. 28.8% participants reported having at least one AEFI. Most AEFIs were minor reactions (28.4%) while there were only 47% participants experienced severe AEFIs. The proportion of participants suffering AEFIs peaked in the first 24 hours post injection and just a few symptoms lasted more than 2 days. The most common AEFIs were pain at injection site (22.8%), headache (19.6%), muscle pain (187%), fever with temperature at least 37.5oC (13.3%) and chills (11.6%). Data analysis demonstrated that there was a significant association between age and the proportion of AEFIs (p=0.001). There was no significant difference between male and female in the percentage of AEFIs (p=0.353). Conclusion: Most of AEFIs associated with COVID-19 vaccine AstraZeneca were minor reactions and developed in the first 24 hours post vaccination. There was an association between age and the incidence of AEFIs. Young adults were more likely to suffer from AEFIs than elderly.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR